Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvation Bio, Inc.

2.46
+0.19008.37%
Post-market: 2.470.0100+0.41%18:45 EDT
Volume:5.90M
Turnover:14.43M
Market Cap:835.58M
PE:-1.16
High:2.54
Open:2.31
Low:2.31
Close:2.27
Loading ...

Nuvation Bio's Taletrectinib Secures Approval in China for Lung Cancer Treatment

MT Newswires Live
·
07 Jan

BRIEF-Nuvation Bio Receives Approval From China's National Medical Products Administration For Taletrectinib For Patients With Advanced ROS1-Positive Non-Small Cell Lung Cancer

Reuters
·
06 Jan

Nuvation Bio Inc - Taletrectinib to Be Marketed in China by Innovent Biologics

THOMSON REUTERS
·
06 Jan

Nuvation Bio Receives Approval From China’s National Medical Products Administration for Taletrectinib for Patients With Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
06 Jan

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Business Wire
·
06 Jan

Nuvation Bio Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Jan

Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now?

Insider Monkey
·
31 Dec 2024

Sector Update: Health Care Stocks Fall Premarket Monday

MT Newswires Live
·
23 Dec 2024

Nuvation Bio's Lung Cancer Drug Candidate Taletrectinib Gets FDA Priority Review

MT Newswires Live
·
23 Dec 2024

FDA accepts Nuvation Bio’s NDA for taletrectinib to treat ROS1+NSCLC

TIPRANKS
·
23 Dec 2024

Nuvation Bio Inc - FDA Assigns Target Action Date of June 23, 2025

THOMSON REUTERS
·
23 Dec 2024

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
23 Dec 2024

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Business Wire
·
23 Dec 2024

Innovent Receives Approval of Dovbleron® (Taletrectinib Adipate Capsule, Ros1 Inhibitor) by China's National Medical Products Administration

THOMSON REUTERS
·
20 Dec 2024

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Business Wire
·
26 Nov 2024

Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?

Simply Wall St.
·
21 Nov 2024

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Business Wire
·
13 Nov 2024

Nuvation Bio’s Global Challenges: Navigating Risks in China Amid Geopolitical Tensions

TIPRANKS
·
08 Nov 2024

Nuvation Bio Is Maintained at Outperform by RBC Capital

Dow Jones
·
08 Nov 2024

RBC Capital Adjusts Price Target on Nuvation Bio to $6 From $5, Maintains Outperform, Speculative Risk Rating

MT Newswires Live
·
07 Nov 2024